Corona Remedies' Q2 FY 2025-26 Quarterly Results
- 06 Jan 2026
Result Summary
- Corona Remedies Ltd reported a 4.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a - of -.
- Its expenses for the quarter were up by 2.1% QoQ and - - YoY.
- The net profit increased 13.2% QoQ and - - YoY.
- The earnings per share (EPS) of Corona Remedies Ltd stood at 8.55 during Q2 FY 2025-26.
Financial Statments for Q2 FY 2025-26
Total Income | 363.40 | 348.56 | 0.00 | 4.3% | - |
Total Expenses | 293.79 | 287.67 | 0.00 | 2.1% | - |
Profit Before Tax | 69.61 | 60.89 | - | 14.3% | NaN% |
Tax | 17.46 | 14.50 | 0.00 | 20.4% | - |
Profit After Tax | 52.32 | 46.20 | 0.00 | 13.2% | - |
Earnings Per Share | 8.55 | 7.55 | 0.00 | 13.2% | - |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Corona Remedies Ltd is a prominent player in the pharmaceutical industry, primarily focused on the production and distribution of a diverse range of medicinal and healthcare products. The company has carved out a significant presence in the market by offering a variety of pharmaceutical formulations that cater to different therapeutic segments. While specific recent developments in the company are not detailed in the provided data, it is understood that companies in this sector generally engage in continuous research and development to enhance their product offerings and maintain competitiveness. Corona Remedies Ltd, like many of its peers, likely focuses on innovation and expansion to meet the evolving demands of healthcare.
Revenue
The financial data for Corona Remedies Ltd in the second quarter of fiscal year 2026 (Q2FY26) shows a total income of ₹363.40 crores. This represents a quarter-over-quarter (QoQ) increase of 4.3% from the first quarter of fiscal year 2026 (Q1FY26), where total income was ₹348.56 crores. The data for the second quarter of fiscal year 2025 (Q2FY25) is unavailable, so a year-over-year (YoY) comparison cannot be performed. The upward trend in total income from Q1FY26 to Q2FY26 indicates a positive revenue trajectory over the short term.
Profitability
In terms of profitability, Corona Remedies Ltd reported a profit before tax of ₹69.61 crores in Q2FY26, which is a 14.3% increase from the ₹60.89 crores reported in Q1FY26. After accounting for taxes, the profit after tax for Q2FY26 stood at ₹52.32 crores, marking a 13.2% QoQ growth from the previous quarter's figure of ₹46.20 crores. The earnings per share (EPS) for Q2FY26 was ₹8.55, also reflecting a 13.2% increase from the EPS of ₹7.55 in Q1FY26. The tax expense for Q2FY26 was ₹17.46 crores, which showed a 20.4% rise compared to Q1FY26. The data indicates robust profitability growth, with both profit before and after tax showing significant QoQ improvements.
Operating Metrics
The operating metrics for Corona Remedies Ltd, as captured in the provided data, reveal an increase in total expenses from ₹287.67 crores in Q1FY26 to ₹293.79 crores in Q2FY26, which is a 2.1% QoQ rise. This increase in expenses accompanies the rise in total income, suggesting a proportional scaling of operations. Unfortunately, without additional data on other operational aspects such as production volumes or cost efficiencies, further analysis of operational performance cannot be detailed. The financial data does not provide a complete picture of operational metrics such as inventory turnover, receivables, or liquidity ratios, which would typically be considered in a more comprehensive operational analysis.